Allos Drops Oncologic Efaproxyn After Failed Phase III Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will advance chemotherapeutic pipeline that includes Phase II lymphoma treatment PDX.
You may also be interested in...
Allos Plans On Speedy NDA Filing For Cancer Drug Pralatrexate
Compound shows response in Phase II peripheral T-cell lymphoma trial.
Allos Plans On Speedy NDA Filing For Cancer Drug Pralatrexate
Compound shows response in Phase II peripheral T-cell lymphoma trial.
Allos Oncologic Efaproxiral “Approvable” Pending Phase III ENRICH Data
FDA followed the recommendations of its Oncology Drugs Advisory Committee in issuing an “approvable” letter. Efaproxiral approval is also conditional on FDA clearance of Allos’ manufacturing facility and forthcoming agency comments on pharmacology, toxicology and chemistry issues.